Researchers found that the drugs, called Hsp90 inhibitors,
specifically target and inactivate a mechanism commonly used by prostate
cancer cells to evade the effects of standard treatment.
The findings provide vital information about the role of Hsp90 in
drug-resistant prostate cancers, and open up potential new routes to
cancer treatment based on blocking this or related proteins.
A team at The Institute of Cancer Research, London, found that Hsp90
inhibitors countered the effect of malfunctions in the androgen
receptor, which often occur in resistance to hormone treatments.
The research suggests that Hsp90 inhibitors could be effective in
prostate cancers that have become resistant to treatment and started
spreading round the body.
Hsp90 inhibitors are among several innovative new types of treatment
designed to attack cancer indirectly, by destabilising multiple
different proteins required for the growth and survival of cancer cells. By destroying several cancer signals at once, they are designed to
make it hard for cancers to escape the effects of treatment, giving them
promise as potential 'resistance-busting' drugs.
No comments:
Post a Comment